Futura Medical (FUM)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

34.85p
   
  • Change Today:
    -0.60p
  • 52 Week High: 65.00
  • 52 Week Low: 25.50
  • Currency: UK Pounds
  • Shares Issued: 301.45m
  • Volume: 408,913
  • Market Cap: £105.06m
  • RiskGrade: 479

Futura Medical points to £1bn potential annual erectile gel sales

By Oliver Haill

Date: Monday 06 Mar 2017

LONDON (ShareCast) - (ShareCast News) - Futura Medical has commissioned market research that has suggested gel treatment for erectile dysfunction has potential to be sold as an over-the-counter product, with potential peak sales of more than $650m a year.
Ipsos came to the valuation based on primary market research carried out amongst 400 men with erectile dysfunction or suspected erectile dysfunction in the USA.

Futura expects to begin Phase III trials later this year of the standard and increased strength dosage forms of the gel, currently called MED2002, in at least 700 patients, subject to confirmation from regulatory authorities.

The AIM-listed company remains in talks about out-licensing the product.

Ipsos's healthcare forecasting model has been demonstrated by Ipsos to be within 20% of actual sales volumes in nine out of 10 of its forecasts.

In a market where Viagra is a dominant brand, the key findings of the Ipsos research showed that the respondents believed that the product is highly differentiated from existing products and that its claims would meet their needs.

"MED2002's rapid onset of action, an average of less than five minutes, was the key feature that attracted respondents to the product and could command a price premium compared with existing ED treatments, which have a substantially slower onset of action."

The Ipsos forecast comes on top of earlier market research that estimated the product would have a prescription market size of up to US$600m in key countries worldwide.

Ipsos forecasts that 70% of OTC product sales will be incremental to the prescription ED category, putting the combined estimates for MED2002's peak annual sales at more than $1bn.

Chief executive James Barder said: "Our belief is that the standard dosage form could be switched, at an appropriate time, from a prescription to an over-the-counter medicine. The Ipsos market research has focused on the potential of MED2002 as an over-the-counter medicine."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Futura Medical Market Data

Currency UK Pounds
Share Price 34.85p
Change Today -0.60p
% Change -1.69 %
52 Week High 65.00
52 Week Low 25.50
Volume 408,913
Shares Issued 301.45m
Market Cap £105.06m
RiskGrade 479

Futura Medical Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
47.16% below the market average47.16% below the market average47.16% below the market average47.16% below the market average47.16% below the market average
9.8% below the sector average9.8% below the sector average9.8% below the sector average9.8% below the sector average9.8% below the sector average
Price Trend
2.18% above the market average2.18% above the market average2.18% above the market average2.18% above the market average2.18% above the market average
60.71% above the sector average60.71% above the sector average60.71% above the sector average60.71% above the sector average60.71% above the sector average
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 1
Buy 1
Neutral 0
Sell 0
Strong Sell 0
Total 2
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Futura Medical Dividends

No dividends found

Trades for 29-Apr-2024

Time Volume / Share Price
16:35 9,297 @ 34.85p
16:35 3,064 @ 34.85p
16:35 1,233 @ 34.85p
16:35 703 @ 34.85p
16:35 2,913 @ 34.85p

Futura Medical Key Personnel

CEO James Henry Barder
Finance Director Angela Hildreth

Top of Page